# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | Ramsay Health Care Limited |
| Establishment Date | 1964, N/A, N/A |
| Headquarters Location | 悉尼, 澳大利亚 |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | Ramsay Health Care正在进行数字和数据转型计划，旨在提升患者、医生和员工的体验。该计划包括实施Ramsay Health Hub和患者跟踪系统，以增强数字能力和改善服务交付。 | Ramsay Santé在2023年推出了Living Labs，作为创新的孵化器，旨在优先考虑可扩展的创新并加速实际测试。这些实验室网络包括法国和北欧的九个中心，专注于初级护理、心理健康和肿瘤学团队的创新。 |
| Product Advantages | Ramsay的产品组合包括心理健康、日间手术和急救中心等服务，致力于提供高质量的临床护理和患者体验。公司在多个关键领域（如骨科、癌症和心脏病）扩大市场领导地位。 | Ramsay的数字和数据转型战略旨在创建一个最佳的数字化医疗生态系统，以提升患者体验和临床结果。该战略包括建立Ramsay Australia Health Hub和Ramsay Australia Data Hub，以整合和利用数据。 |
| Brand Recognition | Ramsay在全球范围内被视为领先的医疗服务提供商，致力于提供卓越的患者体验，并在多个地区保持高水平的净推荐值（NPS），反映出强大的客户忠诚度和良好的口碑。 | Ramsay在2023年被评为澳大利亚十大最具吸引力的雇主之一，反映了其在员工吸引力和满意度方面的良好声誉。 |
| Reputation Ratings | Ramsay的可持续发展目标与联合国可持续发展目标（SDGs）相一致，致力于减少温室气体排放，并在FY24达成了减少排放的目标。 | Ramsay在2023年获得了多个ESG相关的认可，包括在可持续发展目标（SDGs）方面的承诺，并通过EcoVadis对40%的供应商进行了可持续性评估。 |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | N/A |
| Vision Statement | To be a leading healthcare provider of the future |
| Core Values | 可持续性 |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 16,660.2 | 14,963.9 | 13,312.4 | Millions | AUD |
| Cost of Goods Sold | (15,774.5) | (14,327.8) | (12,864.2) | Millions | AUD |
| Gross Profit | N/A | N/A | N/A | Millions | AUD |
| Operating Expense | N/A | N/A | N/A | Millions | AUD |
| Operating Income | 1,004.6 | 1,041.3 | 912.2 | Millions | AUD |
| Net Profit | 881.4 | 365.5 | 379.2 | Millions | AUD |
| Income before income taxes | 384.6 | 527.1 | 523.2 | Millions | AUD |
| Income tax expense(benefit) | (121.3) | (181.5) | (159.3) | Millions | AUD |
| Interest Expense | (620.0) | (514.2) | N/A | Millions | AUD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 20,894.0 | 21,030.2 | 19,514.5 | Millions | USD |
| Current Assets | 3,872.8 | 3,895.8 | 3,285.5 | Millions | USD |
| Non-Current Assets | 17,021.2 | 17,134.4 | 16,229.0 | Millions | USD |
| Total Liabilities | 15,366.5 | 16,207.0 | 14,988.3 | Millions | USD |
| Current Liabilities | 4,180.3 | 3,810.4 | 3,747.6 | Millions | USD |
| Non-Current Liabilities | 11,186.2 | 12,396.6 | 11,240.7 | Millions | USD |
| Shareholders' Equity | 5,527.5 | 4,823.2 | 4,526.2 | Millions | USD |
| Retained Earnings | 2,500.2 | 1,786.7 | 1,708.7 | Millions | USD |
| Total Equity and Liabilities | 20,894.0 | 21,030.2 | 19,514.5 | Millions | USD |
| Inventories | 379.4 | 388.6 | 376.8 | Millions | USD |
| Prepaid Expenses | 234.3 | 191.7 | 186.4 | Millions | USD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 668.1 | 744.5 | 237.7 | Millions | USD |
| Net Cash Flow from Investing | (287.9) | (220.5) | (730.7) | Millions | USD |
| Net Cash Flow from Financing | (372.5) | (172.0) | (239.2) | Millions | USD |
| Net Increase/Decrease in Cash | 7.7 | 352.0 | (732.2) | Millions | USD |
| Dividends | (158.3) | (236.8) | (351.9) | Millions | USD |


## S2.4: Key Financial Metrics

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Gross Margin | 194.68% | 195.75% | 196.63% | Millions | AUD |
| Operating Margin | 6.03% | 6.96% | 6.85% | Millions | AUD |
| Net Profit Margin | 5.29% | 2.44% | 2.85% | Millions | AUD |
| Current Ratio | 92.64% | 102.24% | 87.67% | Millions | AUD |
| Quick Ratio | 77.96% | 87.01% | 72.64% | Millions | AUD |
| Interest Coverage | 162.03% | 202.51% | N/A | Millions | AUD |
| Asset Turnover | 79.48% | 73.81% | N/A | Millions | AUD |
| Debt-to-Equity | 278.00% | 336.02% | 331.15% | Millions | AUD |
| Return on Equity | 17.03% | 7.82% | N/A | Millions | AUD |
| Return on Assets | 4.20% | 1.80% | N/A | Millions | AUD |
| Effective Tax Rate | 31.54% | 34.43% | 30.45% | Millions | AUD |
| Dividend Payout Ratio | 17.96% | 64.79% | 92.80% | Millions | AUD |

## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | Revenue from contracts with customers：$16,660.2m，Other income - income from government grants：$99.6m，Other income - income from sale of development assets：$5.2m，Other Income - net profit on disposal of non-current assets and acquisition of businesses：$7.1m | Revenue from contracts with customers：$14,963.9m，Other income - income from government grants：$290.2m，Other income - income from sale of development assets：$14.9m，Other income - net profit on disposal of non-current assets and acquisition of businesses：$60.3m | Revenue from contracts with customers：$13,312.4m，Other income - income from government grants：$402.0m，Other income - income from sale of development assets：$1.8m，Other income - net profit on disposal of non-current assets and acquisition of businesses：$23.8m |
| Revenue by Geographic Region | Australia：$6,042.3m，UK：$2,360.8m，France：$5,663.5m，Nordics：$2,593.6m | Australia：$5,682.9m，UK：$1,941.2m，France：$5,007.6m，Nordics：$2,332.2m | Australia：$5,343.7m，UK：$1,321.5m，France：$4,646.3m，Nordics：$2,000.9m |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | 从2022年到2024年，公司的收入呈现出持续增长的趋势，2024年的收入为16660.2百万美元，相较于2023年的14963.9百万美元和2022年的13312.4百万美元均有所增加。毛利率略有下降，从2022年的196.63%降至2024年的194.68%。按产品/服务分解，2024年来自客户合同的收入显著增加至16660.2百万美元，而政府补助收入和其他收入则有所减少。按地理区域分析，澳大利亚的收入从2022年的5343.7百万美元增长至2024年的6042.3百万美元，显示出强劲的市场表现。 |
| Operating Efficiency | 营业利润率在2022年至2024年间略有波动，2024年的营业利润率为6.03%，低于2023年的6.96%和2022年的6.85%。尽管营业收入在增长，但营业利润的增长速度未能跟上收入的增长，显示出成本管理的有效性可能存在一定的挑战。 |
| External & One-Off Impact | 有效税率在2022年至2024年间有所波动，2024年的有效税率为31.54%，高于2023年的34.43%和2022年的30.45%。此外，2024年净利润为881.4百万美元，较2023年的365.5百万美元显著增长，但仍低于2022年的379.2百万美元，表明外部因素可能对盈利能力产生了影响，尤其是在税务和非经常性项目方面。 |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | 2024年总资产为20894.0千万元，较2023年的21030.2千万元略有下降。总负债为15366.5千万元，较2023年的16207.0千万元有所减少，显示出负债水平的改善。股东权益增加至5527.5千万元，表明公司财务健康状况有所增强。流动比率为92.64%，显示流动性略有下降，但仍在可接受范围内。 | 2023年总资产为21030.2千万元，较2022年的19514.5千万元有所增长。总负债为16207.0千万元，较2022年的14988.3千万元有所增加，表明负债水平上升。股东权益为4823.2千万元，显示出公司在权益方面的稳定性。流动比率为102.24%，表明流动性良好。 |
| Profitability and earnings quality | 2024年收入为16660.2千万元，净利润为881.4千万元，净利润率为5.29%，显示出盈利能力的提升。营业收入较2023年增长，尽管营业利润有所下降，但整体盈利质量仍然保持在较高水平。 | 2023年收入为14963.9千万元，净利润为365.5千万元，净利润率为2.44%。尽管收入有所增长，但净利润率较2022年有所下降，显示出盈利能力的压力。 |
| Operational efficiency | 2024年营业利润为1004.6千万元，营业利润率为6.03%。资产周转率为79.48%，显示出公司在资产利用方面的效率有所提升，但整体营业效率仍需关注。 | 2023年营业利润为1041.3千万元，营业利润率为6.96%。资产周转率为73.81%，显示出公司在资产利用方面的效率有所下降，需加强营运效率管理。 |
| Financial risk identification and early warning | 2024年负债权益比为278.00%，显示出公司财务杠杆水平有所降低，流动性风险有所缓解。有效税率为31.54%，较2023年有所下降，表明税务管理的改善。 | 2023年负债权益比为336.02%，显示出公司财务杠杆水平较高，流动性风险需关注。有效税率为34.43%，表明税务负担较重。 |
| Future financial performance projection | 2024年公司计划继续进行投资活动，尽管投资现金流为负，但经营现金流为668.1千万元，显示出公司在经营活动中的现金流稳定。未来的财务表现展望依赖于持续的收入增长和有效的成本控制。 | 2023年公司在投资和融资方面的现金流均为负，经营现金流为744.5千万元，显示出公司在经营活动中的现金流状况良好。未来财务表现需关注收入增长和成本控制的平衡。 |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | Ramsay primarily derives revenue from providing healthcare and related services to both public and private patients in the community. The main sources of revenue include contracts with customers, rental income, and ancillary services. In FY24, revenue from contracts with customers was A$16,660.2 million, with A$6,042.3 million from Australia, A$2,360.8 million from the UK, A$5,663.5 million from France, and A$2,593.6 million from the Nordics. Additionally, rental income is recognized on a straight-line basis over the lease term, contributing to the overall revenue. | The company primarily derives revenue from providing health care and related services to both public and private patients in the community. Revenue is generated through contracts with customers, rental income, and ancillary services. Specific revenue streams include revenue from patients amounting to $14,379.6 million, rental revenue of $99.2 million, and revenue from ancillary services totaling $483.4 million. |
| Market Position | Ramsay is positioned as a market leader in the healthcare sector, benefiting from favorable dynamics underpinning the long-term outlook for the industry. The company reported a net profit after tax from continuing operations of A$270.6 million in FY24. Ramsay's growth strategy is supported by its multinational platform, strategic relationships, and commitment to clinical excellence, which enhances its competitive advantage. The company is focused on optimizing and driving greater value from its core hospital network while improving patient experience and operational efficiencies. | The company is positioned as a leading healthcare provider, leveraging its global platform to capitalize on megatrends in the healthcare sector. It operates in multiple regions including Asia Pacific, the UK, France, and the Nordics, with total revenue of $15,339.1 million. The company is focused on operational excellence and has a strong organizational foundation, indicating a competitive advantage in the healthcare market. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | Ramsay's growth strategy may be impacted by industry disruption, innovation, the actions of competitors, or the ability to identify future acquisitions or generate returns on developments. Additionally, macroeconomic factors such as wage, supply cost, and energy price inflation, as well as changes to interest rates, could materially affect financial performance. | The Group faces market risks related to interest rate fluctuations, particularly due to its long-term debt obligations with floating interest rates. Additionally, foreign currency risk arises from operating activities when revenues or expenses are denominated in currencies different from the functional currency. |
| Operational Risks | Ramsay's global operations rely on international supply chains, which may be affected by geopolitical tensions and economic conditions, impacting cost and availability of supplies. The company also faces risks related to workforce shortages, which can disrupt operations and affect service delivery. | Ramsay's operations are impacted by workforce shortages, particularly in nursing and clinical roles, exacerbated by the COVID-19 crisis. The reliance on international supply chains also poses risks related to geopolitical tensions and severe weather, which may disrupt supply and affect healthcare provision. |
| Financial Risks | The Group is exposed to interest rate risk primarily through its long-term debt obligations with floating interest rates. Credit risk arises from potential defaults by counterparties, and liquidity risk is managed through cash flow forecasts and credit policies. The Group uses derivatives to hedge against interest rate and foreign exchange risks. | The Group is exposed to various financial risks including interest rate risk, credit risk, and liquidity risk. Management actively monitors these risks and employs strategies such as entering into derivative contracts to hedge against fluctuations in interest and foreign exchange rates. The Group's liquidity position is regularly reviewed to ensure it can meet its financial obligations. |
| Compliance Risks | Ramsay operates in a heavily regulated healthcare environment, subject to extensive laws and regulations that may vary by jurisdiction. Changes in government policy could materially impact the provision of healthcare and the affordability of private health insurance. | Ramsay operates in a highly regulated industry, requiring compliance with extensive laws and regulations. The potential for litigation and disputes with patients, suppliers, and regulatory bodies presents ongoing compliance challenges. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Craig McNally | Managing Director & CEO | £3,391,706,000 |
| Martyn Roberts | Group CFO | £1,500,000,000 |
| Henrietta Rowe | Group General Counsel & Company Secretary | N/A |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | Climate-related risks are identified, assessed and managed at a Group level, with input from project- and regional-level stakeholders. The Global Risk Management Committee oversees and reports progress against regional Net Zero Plans as part of Corporate Plan 2030 and development of Transition Plans. Qualitative and quantitative assessments are undertaken, including workshops with senior leaders to review risks and opportunities. | The Group's risk management framework includes a high-level risk and opportunity assessment to identify a range of physical risks, as well as climate change risks. The approach is guided by the Task Force on Climate-related Financial Disclosures (TCFD) recommendations. |
| Control activities | The Group manages its exposure to key financial risks, including market risk, credit risk, and liquidity risk in accordance with the Group's financial risk management policy. The Audit Committee is responsible for the identification and control of financial risks, and the Board reviews and agrees on policies for managing these risks. | The Group implements a compliance framework that includes policies, training, incident management, monitoring, and reporting of safety performance. The Audit Committee is responsible for the identification and control of financial risks, with the Board reviewing and agreeing on policies for managing these risks. |
| Monitoring mechanisms | The Audit Committee and Risk Management Committee oversee the internal control systems. The auditor evaluates the appropriateness of accounting policies and assesses the risks of material misstatement, while also communicating significant audit findings to the directors. | The effectiveness of internal controls is monitored through the Audit Committee, which reviews the financial report and communicates significant audit findings, including any deficiencies in internal control identified during the audit. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | The directors are responsible for ensuring that internal controls are in place to prepare financial reports that are free from material misstatement. The auditor's report indicates that the financial report is in accordance with the Corporations Act 2001 and complies with Australian Accounting Standards. | The directors are responsible for ensuring that internal controls are in place to prepare a financial report that is free from material misstatement. The auditors provide reasonable assurance regarding the financial report's accuracy, but do not express an opinion on the effectiveness of the Group's internal control. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | 在2024财年，集团在澳大利亚和欧洲收购了某些医疗保健业务，这些业务均属于医疗保健行业。 | Ramsay的增长部分得益于在医疗保健行业内的收购。2023年6月28日，Ramsay宣布与其50:50合资伙伴Sime Darby Berhad共同探索出售Ramsay Sime Darby的可能性。 |
| New technologies | Ramsay正在进行数字和数据转型计划，实施了Ramsay Health Hub和患者追踪系统，以增强患者、医生和员工的体验。 | Ramsay正在加速其数字和运营转型项目，重点是改善澳大利亚的业绩。数字和数据战略包括建立Ramsay Australia Health Hub，推出国家心理健康数字入院系统，以及在瑞典的Capio Sankt Göran医院使用人工智能算法进行乳腺癌筛查。 |
| Organisational Restructuring | Ramsay继续投资于人才管理和培养项目，包括全球和地区领导力学院，以吸引、发展和留住合适的人才。 | Ramsay致力于在每个阶段培养世界级的领导者，以勇敢地领导并实现组织战略。2023年，Ramsay推出了新的领导力学院，并在澳大利亚、欧洲和英国启动了新的领导力培训项目。 |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | Ramsay's cost base is subject to various levels of wage, supply cost, and energy price inflation, as well as changes to interest rates on its debt. Material changes in inflation and/or interest rates could significantly impact Ramsay's financial performance, leading to limited growth or inability to maintain earnings, difficulty in attracting and retaining employees, and increased costs associated with wage negotiations and high inflation levels. Additionally, geopolitical tensions and inflation may cause cost increases, and international sanctions could impact supply availability. | Ramsay's cost base is subject to various levels of wage, supply cost, and energy price inflation, as well as changes to interest rates on its debt. Material changes in inflation and/or interest rates could significantly impact financial performance. Additionally, geopolitical tensions and global economic conditions may affect the cost, availability, and sustainability of supply, impacting healthcare provision. The company faces ongoing discussions with payors to ensure that higher costs are reflected in reimbursement rates, particularly in light of inflationary pressures. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | Ramsay's growth strategy may be impacted by industry disruption, innovation, and the actions of competitors. The entry of new digitally-enabled, lower-cost competitors poses a significant threat, and there is ongoing pressure to improve service delivery compared to competitors. The NHS tariff indexation in the UK is below inflation, which may challenge earnings growth despite expected volume increases. Ramsay is also facing competition for skilled labor, which could impact capacity utilization. | Ramsay faces competition from both existing industry players and new entrants, particularly those leveraging digital technologies to offer lower-cost services. The company must navigate industry disruption and innovation while maintaining its market position. The emergence of new competitors and the need for continuous clinical innovation are critical factors that could limit growth or impact service delivery. Additionally, Ramsay's growth strategy may be affected by its ability to identify future acquisitions or generate returns on developments. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | In FY24, Ramsay Health Care invested $286m in brownfield and greenfield projects, focusing on expanding treatment capacity and digital transformation programs, particularly in Australia. The investment aimed to enhance productivity, customer satisfaction, and prepare for a wider electronic health records deployment. | In 2023, Ramsay Health Care Limited focused on digital and data transformation, with a total capital expenditure of $328.6 million, including $29.7 million specifically for digital and data initiatives. The company emphasized investments in brownfield and greenfield developments, while also moderating spending due to increased development costs. The digital strategy aims to enhance operational efficiency and patient care through various projects, including an online patient hub and predictive analytics for clinical coding. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | Ramsay Health Care launched the Ramsay Health Hub, a digital front door for patients, and implemented a Patient Tracking system, enhancing patient experience with real-time updates. By mid-2024, 50,000 patients had used the online pre-admission feature, and over 38,000 opted for Patient Tracking, indicating significant market differentiation. | Ramsay Santé launched Living Labs in 2023 to foster innovation in healthcare. These labs serve as incubators for scalable innovations, focusing on improving surgical pathways and documentation efficiency. Notable projects include a mobile app for addiction support at the Saint Barnabé clinic and the reopening of the Ange Gardien mental health clinic, which enhances mental health services in the Ile-de-France region. |
